Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, issue.8, pp.707-721, 2012. ,
Resistance to RAF inhibitors revisited, J Invest Dermatol, vol.134, issue.2, pp.319-344, 2014. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, issue.26, pp.2507-2523, 2011. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, issue.6892, pp.949-54, 2002. ,
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma, J Clin Oncol, vol.31, issue.14, pp.1767-74, 2013. ,
Evaluation of multiple serum markers in advanced melanoma, Tumour Biol, vol.32, issue.6, pp.1155-61, 2011. ,
Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab, Radiology, vol.270, issue.2, pp.425-459, 2014. ,
Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors, Clin Chem, vol.61, issue.1, pp.297-304, 2015. ,
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/ MEK inhibitors, J Transl Med, vol.14, p.95, 2016. ,
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance, Ann Oncol, vol.26, issue.7, pp.1470-1475, 2015. ,
Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al, Ann Oncol, vol.27, issue.2, pp.363-367, 2016. ,
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma, Target Oncol, vol.11, issue.1, pp.59-69, 2016. ,
Clinical pharmacokinetics of Vemurafenib, Clin Pharmacokinet, 2017. ,
Plasma vemurafenib exposure and pretreatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients, Pharmacol Res, vol.113, pp.709-727, 2016. ,
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients, J Chromatogr B Analyt Technol Biomed Life Sci, vol.928, pp.93-100, 2013. ,
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number, Anal Chem, vol.83, issue.22, pp.8604-8614, 2011. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, issue.12, pp.1722-1753, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Determining lower limits of detection of digital PCR assays for cancer-related gene mutations, Biomol Detect Quantif, vol.1, issue.1, pp.8-22, 2014. ,
Multiplex detection of rare mutations by Picoliter droplet based digital PCR: sensitivity and specificity considerations, PLoS One, vol.11, issue.7, p.159094, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299556
Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline, Exp Dermatol, vol.25, issue.10, pp.783-791, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01408920
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Sci Rep, vol.5, p.11198, 2015. ,
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma, Mol Cancer, vol.14, p.27, 2015. ,
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma, Br J Cancer, vol.111, issue.2, pp.292-301, 2014. ,
Clinical pharmacokinetics of Vemurafenib in BRAF-mutated melanoma patients, J Clin Pharmacol, vol.57, issue.1, pp.125-133, 2017. ,
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics, J Clin Pharmacol, vol.54, issue.4, pp.368-74, 2014. ,